Xenon Pharmaceuticals Inc. (XENE)
After hours:
- Zacks
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 7.89% and 4.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022 Company-sponsored Phase 2 Clinical Trial Initiated to Evaluate XEN1101 for the Treatment of MDD Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ende
- Zacks
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
